Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072713 | 0.81 | CYP2D6 (0.45) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL5068661 | 0.76 | GAA (0.62) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| P-Xylene SCHEMBL8660591 | 0.76 | GAA (0.62) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL1705904 | 0.76 | GAA (0.62) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL34 | 0.76 | GAA (0.62) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL29991938 | 0.76 | GAA (0.62) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL11432043 | 0.76 | GAA (0.62) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL31313 | 0.76 | GAA (0.62) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL27831752 | 0.76 | CYP2D6 (0.51) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL7635097 | 0.75 | CYP2D6 (0.53) | CYP2D6ALDH1A1HTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498433-B2 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2009-03-03 | — | — | US | disclosed |
| EP-1594879-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA TOVARNA ZDRAVIL D D NOVO (SI) | 2008-10-22 | — | — | EP | disclosed |
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL D.D. (SI) | 2006-02-23 | — | — | US | disclosed |
| EP-1594879-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004065390-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | CYP4F11, CYP4A11, CYP3A4 | CYP2D6 51/4885ALDH1A1 769/4885HTT 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.